Robert Hamilton Pierce, M.D.
Scientific Advisory Board
Dr. Pierce is experienced in managing large teams dedicated to developing disease-oriented and tissue-based translation medicine platforms. Dr. Pierce recently was appointed as a Member of the Fred Hutchinson Cancer Research Center and the Scientific Director of the Immunopathology Lab. Previously, he was the Chief Scientific Officer (CSO) of OncoSec Medical Incorporated. Prior to joining OncoSec, Dr. Pierce was at Merck Research Labs, contributing to multiple successful immunology and oncology IND applications. Most notably, Dr. Pierce was a key member of the MK-3475 (pembrolizumab) project team and was instrumental in the development of biomarker approaches to defining response and non-response phenotypes to anti-PD1 blockade, including the 22C3 PD-L1 companion diagnostic IHC assay. He also participated in the design of two Phase 2 anti-PD-1 (MK-3475) oncology studies in collaboration with CITN, the Cancer Immunotherapy Trials Network. Dr. Pierce is a graduate of Yale College and Brown University School of Medicine. Following graduation from medical school, he completed a residency program in Anatomic Pathology and a post-doctoral research fellowship at the University of Washington in Seattle, WA.